<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pelthos Therapeutics Inc. — News on 6ix</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc</link>
<description>Latest news and press releases for Pelthos Therapeutics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 10 Apr 2026 21:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pelthos-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d77bcf51cc36e475340b13.webp</url>
<title>Pelthos Therapeutics Inc.</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc</link>
</image>
<item>
<title>Pelthos Therapeutics Announces CFO Transition</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-announces-cfo-transition</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-announces-cfo-transition</guid>
<pubDate>Fri, 10 Apr 2026 21:00:00 GMT</pubDate>
<description>Senior Vice President, Finance & Accounting John M. Gay named Chief Financial OfficerDURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced John M. Gay has been appointed Chief Financial Officer effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II, who served as Pelthos’ Chief Financial Officer since Jul</description>
</item>
<item>
<title>Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-ct2000-in-eye-pain</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-ct2000-in-eye-pain</guid>
<pubDate>Tue, 31 Mar 2026 12:30:00 GMT</pubDate>
<description>First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a lead pipeline asset of Channel Therapeutics, a Pelthos subsidiary DURHAM, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announc</description>
</item>
<item>
<title>Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Mar 2026 10:30:00 GMT</pubDate>
<description>ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025. 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in units dispensed, rising from 2,716 units in the third quarter of 2025 to 6,232 units in the f</description>
</item>
<item>
<title>Pelthos Therapeutics to Present at 38th Annual ROTH Conference</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-present-at-38th-annual-roth-conference-5</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-present-at-38th-annual-roth-conference-5</guid>
<pubDate>Thu, 12 Mar 2026 12:30:00 GMT</pubDate>
<description>DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time. Investors interested in arranging one-on-one meetings should contact their ROTH representative. A live webcast of the fire</description>
</item>
<item>
<title>Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026</guid>
<pubDate>Mon, 09 Mar 2026 12:30:00 GMT</pubDate>
<description>Company to hold a conference call at 8:00 a.m. ETDURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. The company will hold a conference call followed by a question-and-answer period at 8:00 a.m. Eastern Time. Details</description>
</item>
<item>
<title>Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that its CEO, Scott Plesha, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 10:00 a.m. Eastern Time. The Pelthos management team is scheduled to host one-on-one meetings with investors and attendees during</description>
</item>
<item>
<title>Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/horizon-technology-finance-provides-up-to-dollar50-million-venture-loan-facility-to-pelthos-therapeutics-2</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/horizon-technology-finance-provides-up-to-dollar50-million-venture-loan-facility-to-pelthos-therapeutics-2</guid>
<pubDate>Thu, 15 Jan 2026 21:10:00 GMT</pubDate>
<description>FARMINGTON, Conn., January 15, 2026--Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) ("Pelthos"), with an initial funding of $30 million, and up to $20 million to support future growth.</description>
</item>
<item>
<title>Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-secures-up-to-dollar50-million-senior-secured-term-loan-facility-from-horizon-technology-finance</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-secures-up-to-dollar50-million-senior-secured-term-loan-facility-from-horizon-technology-finance</guid>
<pubDate>Tue, 13 Jan 2026 13:30:00 GMT</pubDate>
<description>The minimally dilutive funding will accelerate Pelthos’ highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposesDURHAM, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative the</description>
</item>
<item>
<title>Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-acquires-xeglyzer-abametapir-topical-treatment-for-head-lice</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-acquires-xeglyzer-abametapir-topical-treatment-for-head-lice</guid>
<pubDate>Mon, 05 Jan 2026 12:30:00 GMT</pubDate>
<description>Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired Xeglyze® (abameta</description>
</item>
<item>
<title>Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-expands-board-of-directors-with-the-appointment-of-andrew-einhorn</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-expands-board-of-directors-with-the-appointment-of-andrew-einhorn</guid>
<pubDate>Tue, 23 Dec 2025 22:57:00 GMT</pubDate>
<description>Seasoned executive brings four decades of finance, capital markets, and life sciences experienceDURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelt</description>
</item>
<item>
<title>Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-signs-major-pharmacy-benefit-manager-agreement-expanding-patient-access-to-zelsuvmitm-berdazimer-topical-gel-103percent</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-signs-major-pharmacy-benefit-manager-agreement-expanding-patient-access-to-zelsuvmitm-berdazimer-topical-gel-103percent</guid>
<pubDate>Thu, 04 Dec 2025 12:00:00 GMT</pubDate>
<description>ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has sign</description>
</item>
<item>
<title>Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-present-at-the-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-present-at-the-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Tue, 02 Dec 2025 13:00:00 GMT</pubDate>
<description>DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that Pelthos’ CEO Scott Plesha will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference (the “Conference”) on December 4, 2025 at 9:30 a.m. Eastern Time at The Lotte New York Palace located at 455 Madison Avenue, New York, NY 1</description>
</item>
<item>
<title>Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-announces-third-quarter-fiscal-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-announces-third-quarter-fiscal-2025-financial-results</guid>
<pubDate>Thu, 13 Nov 2025 11:45:00 GMT</pubDate>
<description>Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million in net revenues 2,716 ZELSUVMI units prescribed by 1,169 unique prescribers in the third quarter of fiscal 2025 DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic produc</description>
</item>
<item>
<title>Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-acquires-xepir-ozenoxacin-cream-1percent-and-announces-dollar18-million-private-convertible-notes-financing</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-acquires-xepir-ozenoxacin-cream-1percent-and-announces-dollar18-million-private-convertible-notes-financing</guid>
<pubDate>Fri, 07 Nov 2025 13:00:00 GMT</pubDate>
<description>Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting childrenImpetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen in pediatric officesPrivate convertible notes financing will supp</description>
</item>
<item>
<title>Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-report-third-quarter-2025-financial-results-on-november-13-2025</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-report-third-quarter-2025-financial-results-on-november-13-2025</guid>
<pubDate>Wed, 05 Nov 2025 13:00:00 GMT</pubDate>
<description>Company to hold a conference call at 8:00 a.m. ETDURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a conference call on Thursday, November 13, 2025, at 8:00 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to</description>
</item>
<item>
<title>Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-launches-moms-against-molluscum-movement-to-unite-families-affected-by-molluscum-contagiosum</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-launches-moms-against-molluscum-movement-to-unite-families-affected-by-molluscum-contagiosum</guid>
<pubDate>Thu, 09 Oct 2025 12:00:00 GMT</pubDate>
<description>The Moms Against Molluscum movement aims to empower families impacted by molluscum to share their personal stories and encourage others to join the conversationMolluscum is a highly contagious skin infection affecting 16.7 million Americans, mainly childrenMomsAgainstMolluscum.com will offer new resources to support moms, parents, and other caregivers of molluscum patients DURHAM, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company</description>
</item>
<item>
<title>Pelthos Therapeutics to Participate in Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-participate-in-upcoming-september-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-participate-in-upcoming-september-investor-conferences</guid>
<pubDate>Mon, 08 Sep 2025 12:30:00 GMT</pubDate>
<description>DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, CFO, will participate in the upcoming September conferences: H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference. Investor Conference</description>
</item>
<item>
<title>Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-participate-in-the-2025-wells-fargo-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-to-participate-in-the-2025-wells-fargo-healthcare-conference</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>Management’s presentation will take place on Wednesday, September 3rd, 2025 at 1:30 pm (ET)DURHAM, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel, CFO, will participate in the Wells Fargo Healthcare Conference. Management’s presentation will take pla</description>
</item>
<item>
<title>Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-reports-second-quarter-2025-financial-results-for-legacy-operations-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-reports-second-quarter-2025-financial-results-for-legacy-operations-and-provides-business-update</guid>
<pubDate>Mon, 18 Aug 2025 12:00:00 GMT</pubDate>
<description>Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and olderCompletes build-out of essential management operational infrastructure and hires 50 territory sales managers DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum</title>
<link>https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-launches-zelsuvmitm-berdazimer-topical-gel-103percent-the-first-and-only-fda-approved-at-home-treatment-for-molluscum-contagiosum</link>
<guid isPermaLink="true">https://6ix.com/company/pelthos-therapeutics-inc/news/pelthos-therapeutics-launches-zelsuvmitm-berdazimer-topical-gel-103percent-the-first-and-only-fda-approved-at-home-treatment-for-molluscum-contagiosum</guid>
<pubDate>Thu, 10 Jul 2025 12:00:00 GMT</pubDate>
<description>ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the goMolluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them c</description>
</item>
</channel>
</rss>